PRESS RELEASE Stockholm, Sweden, April 20, 2006 Specialized tools designed to help neurosurgeons treat serious disease more aggressively than ever, with full confidence.
Elekta will showcase a complete portfolio of stereotactic solutions at the upcoming annual meeting of the American Association of Neurological Surgeons (AANS) April 22–27, at the Moscone Convention Center in San Francisco, California.
Elekta demonstrates a continued leadership as the only stereotatic solutions provider with specialized tools for treating cancer and other serious diseases in the brain, spine and body. Elekta introduces the new Elekta Axesse™, the world’s only 6D robotic image guided radiosurgery system optimized for treatment of the spine. The new Elekta Axesse system uses exclusive stereotactic technology and true three-dimensional (3D) imaging to ensure fast, efficient and accurate treatment for the patient.
In addition, Elekta will feature Leksell Gamma Knife®, the only gold standard for treating indications of the brain and the world’s only dedicated system for non-invasive radiosurgery. Patients are attracted by its gentle nature, short procedure time and documented clinical results. The patient often leaves the hospital the same day and returns to daily life.
“Neurosurgeons possess rare, important skills and choosing the right stereotactic systems enables them to expand those skills,” says Jim Rose, Elekta Vice President of Marketing for the Americas. “Elekta’s stereotactic systems offer the unrivaled precision neurosurgeons need to treat cancer and other serious disease more aggressively than ever, without increasing risk to healthy tissue.”
Also, Elekta will exhibit several other complementary products for the neurosurgery market, including:
• Leksell® Stereotactic System, the most widely used coordinate frame in the world. It sets standards for accuracy, reliability, versatility and ease-of-use. Elekta’s 3D reference and positioning system is ideal for functional and stereotactic neurosurgery.
• Elekta Neuromag®, the world’s most advanced magnetoencephalography (MEG) system, represents a new standard for combined MEG/EEG devices. Using MEG, it is possible to determine the function of different parts of the brain for each specific patient in the current stage of his or her development.
“Our world-leading portfolio of stereotactic solutions also allows neurosurgeons to enjoy long-term profitability and strong collaboration with the oncology department,” says Rose. “With this portfolio, neurosurgeons can build a Stereotactic Center of Excellence that aligns perfectly with their clinical plans and business objectives.”